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Functionally distinct NKT cell subsets and subtypes
 
Ken-ichiro Seino and Masaru Taniguchi
 
Natural killer T (NKT) cells are a population of autoreactive cells that mediate 
both protective and regulatory immune functions. NKT cells comprise several 
subsets of cells, but it has been unclear whether these different NKT cell 
subsets possess distinct functions in vivo. New studies now demonstrate that 
subsets of NKT cells are indeed functionally distinct and that the specific 
functions of these cells may be dictated in part by organ-specific mechanisms.
 
During their development in the thymus,
conventional 
 
  
 
 T cells acquire the
expression of either CD4 or CD8, ma-
jor histocompatibility complex (MHC)
coreceptors that define functionally
distinct MHC-restricted T cell subsets. In
response to antigen stimulation, CD4
 
 
 
T cells differentiate into T helper (Th)-1
or Th2 cells. Th1 cells produce the
signature cytokine interferon (IFN)-
 
 
 
,
whereas Th2 cells produce interleukin
(IL)-4, IL-5, IL-13, and IL-10. Similarly,
effector CD8
 
 
 
 T cells can be classified
as Tc1 or Tc2 cells, which produce
type 1 or type 2 cytokines, respectively
(1). From this perspective, the cytokine
profiles of T lymphocytes are thought
to reflect their functional activities.
 
Subsets and subtypes of natural killer 
T (NKT) cells
 
NKT cells express an invariant T cell
receptor (TCR) 
 
 
 
 chain (V
 
 
 
14-J
 
 
 
281
in mice and V
 
 
 
24-J
 
 
 
Q in humans) and
recognize glycolipid antigens, such as
the endogenous isoglobotrihexosyl-
ceramide (iGb3) (2) and the synthetic
glycolipid, 
 
 
 
-galactosylceramide (
 
 
 
-Gal-
Cer), in association with the MHC
class I–like molecule CD1d. NKT
cells are different from functionally
differentiated conventional 
 
  
 
 T cells
in that they are autoreactive and produce
both Th1 and Th2 cytokines, including
IL-4, IL-10, and IFN-
 
 
 
, upon stimu-
lation with their ligands (for review
see reference 3). The invariant V
 
 
 
14
 
 
 
NKT cells, also called type I NKT cells
(4), include two defined populations: a
CD4
 
 
 
 and a CD4
 
 
 
CD8
 
 
 
 double nega-
tive (DN) population.
In addition to type I NKT cells, a
population of CD1d-reactive NKT
cells that express diverse non-V
 
 
 
14
TCRs, referred to as type II NKT cells,
has been described. These cells were
identified based on the fact that NKT
cell function was still detectable in
mice lacking type I NKT cells but not
in mice lacking CD1d (4). Although
type II NKT cells are also restricted by
CD1d, they do not recognize 
 
 
 
-Gal-
Cer. It is important to note, however,
that some type II NKT cells are also
autoreactive, as they recognize the
endogenous myelin-derived glycolipid
sulfatide and help protect mice against
the development of experimental au-
toimmune encephalitis (5). Thus, type
I and type II NKT cells appear to have
distinct functional capabilities, but
these functional differences have not
been well characterized.
Type I invariant V
 
 
 
14
 
 
 
 NKT cells
(referred to hereafter as NKT cells)
have been shown to mediate both
protective and regulatory immune
functions. These include tumor rejection,
protection against infectious microbes,
maintenance of transplant tolerance,
and inhibition of autoimmune disease
development (3). However, it remains
unclear whether distinct subsets or
subtypes of CD1d-reactive NKT cells
mediate different functions. Two new
studies, one in a recent issue (6) and
one in this issue (7), suggest that a distinct
subset of NKT cell mediates tumor
rejection (6), and that type II NKT
cells suppress antitumor immunosur-
veillance (7). These new studies might
help explain the seemingly contradictory
functions that have been ascribed to
CD1d-reactive NKT cells. They also
raise new questions about how subsets
of NKT cells acquire distinct functional
capabilities.
 
Tumor rejection by distinct 
NKT cell subsets
 
In a recent study, Crowe and colleagues
compared antitumor activities of NKT
cell subsets from different organs (liver,
thymus, or spleen) against two different
types of tumor cell (methylcholan-
threne-1 sarcoma cells and B16-F10 mel-
anoma  cells) (6). Interestingly, they
found that the DN subset of NKT cells
from the liver were better able to reject
tumor cells than were the CD4
 
 
 
 liver-
derived subset and both the CD4
 
 
 
 and
DN subsets from the thymus or the
spleen,  suggesting that organ-specific
mechanisms might dictate the functional
capabilities of resident NKT cells. In-
deed, past studies have suggested that
NKT cells in other organs may also
have different functions. For example,
thymic DN NKT cells have been shown
to suppress type 1 diabetes development
in NOD mice in an IL-4– and IL-10–
dependent fashion (8). In addition,
splenic CD4
 
 
 
 NKT cells have been
shown to induce CD8
 
 
 
 regulatory T (T
reg) cells that mediate systemic tolerance
in the anterior chamber associated im-
mune deviation (ACAID) model of tol-
erance (9). In the light of new data from
Crowe et al. (6), it will be important
to further clarify whether NKT cell
subsets in different organs mediate
different functions.
The finding that hepatic DN
NKT cells are the primary mediators
of antitumor responses is consistent
with previous findings demonstrating
that human DN NKT cells produce
predominantly Th1 cytokines, whereas
CD4
 
 
 
 NKT cells produce predomi-
nantly Th2 cytokines (10, 11). In most
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models, tumor rejection depends on
IFN-
 
 
 
 production by the NKT cells
and the subsequent IFN-
 
 
 
–induced ac-
tivation of NK cells and CD8
 
 
 
 T cells
(12, 13). However, Crowe et al. found
very little difference in cytokine produc-
tion (IFN-
 
 
 
 and IL-4) among the subsets
of NKT cells in the different tissues (6),
suggesting that factors other than cyto-
kine production might be involved in
NKT cell–mediated tumor rejection. It is
important to note, however, that al-
though IL-4 production did not differ
significantly between the various subsets
of NKT cells, thymic NKT cells from
IL-4–deficient mice acquired the ability
to reject tumors (6), suggesting that the
production of IL-4 might inhibit certain
antitumor responses in vivo. However,
molecules other than IL-4 must also con-
tribute to the inhibition of NKT cell–
mediated antitumor immunity, as hepatic
DN NKT cells that mediated tumor re-
jection in this model were shown to pro-
duce significant levels of IL-4.
It is unclear whether the different
subsets or types of NKT cells regulate
each other’s functions. However, it
seems likely that the antitumor func-
tion of liver-derived DN NKT cells is
controlled by other subsets or types of
NKT cells, in a manner similar to the
regulatory interplay between Th1 and
Th2 cells.
 
Suppression of tumor rejection by type II 
NKT cells
 
A report by Terabe et al. in this issue
shows that type II NKT cells are re-
sponsible for inhibiting tumor immuno-
surveillance in mice (7). This inhibi-
tion involved IL-13, myeloid cells, and
transforming growth factor–
 
 
 
, but did
not require naturally occurring Foxp3
 
 
 
T reg cells (14). Terabe et al. thus sug-
gest that type II NKT cells may nega-
tively regulate antitumor responses in
mice, whereas type I NKT cells pro-
mote antitumor responses. Although
mutual interactions between these cells
have never been formally studied, it
would be interesting based on these
new results to evaluate whether type II
NKT cells inhibit the protective func-
tion of type I NKT cells in the thymus
or spleen, but not in the liver.
 
Organ-specific functional maturation 
of NKT cell subsets?
 
How do distinct NKT cell subsets, or
NKT cells in different organs, acquire
different functional capabilities? One
possibility is that functionally distinct
NKT cell subsets diverge after their de-
velopment in the thymus. According to
a recent report by Benlagha et al., both
CD4
 
 
 
 and DN NKT cells are derived
from heat stable antigen (HSA)
 
high
 
 dou-
ble positive thymocytes (15). Interest-
ingly, the CD4
 
 
 
 subset is derived di-
rectly from HSA
 
high
 
 double positive
thymocytes, whereas the DN subset ap-
pears to pass through a HSA
 
low
 
 CD4
 
 
 
stage. However, the two subsets of
NKT cells do not seem to acquire dif-
ferent functional potentials in the thy-
mus as, according to Crowe et al., nei-
ther CD4
 
 
 
 nor DN NKT cells from this
organ were able to reject tumors (6).
An alternative possibility is that a
liver-specific mechanism may confer
antitumor potential on resident DN
NKT cells (Fig. 1). In mice, the liver
contains more NKT cells than do
other tissues and these NKT cells
express high baseline levels of the
adhesion molecule lymphocyte func-
tion-associated antigen (LFA)–1 and
the chemokine receptor CXCR6. In
LFA-1 or CXCR6 knockout mice,
the numbers of NKT cells in the liver
were significantly decreased (16–18),
whereas the numbers of these cells
in other organs were normal. These
studies suggested that both LFA-1 and
CXCR6 are selectively required for
the development and/or survival of
liver NKT cells. LFA-1 and CXCR6
also influence the fate and function of
NKT cells by controlling their sur-
vival, cytokine production, and ability
to induce tissue damage. In LFA-1–
deficient mice, for example, Th2 cy-
tokine production by NKT cells was
significantly enhanced (19) and, in
CXCR6 knockout mice, NKT cells
underwent apoptosis and failed to
induce hepatitis in response to con-
canavalin A stimulation (18). There-
fore, the interaction between LFA-
1–intercellular adhesion molecule–1
and/or CXCR6–CXCL16 may con-
tribute not only to the accumulation
of NKT cells in the liver but also to
their acquisition of specialized func-
tions (Fig. 1). In future studies, it will
be important to examine the expres-
sion levels of LFA-1 and CXCR6 on
distinct NKT cell subsets and to deter-
mine whether these molecules influence
their function.
Expression levels of cytotoxic effec-
tor molecules (such as Fas ligand or
TNF), NK cell receptors (such as
CD94 or NKG2D), and chemokine
receptors (such as CCR5 or CCR6)
may also influence the effector function
Figure 1. Potential mechanisms by which tissue-specific NKT cell subsets acquire distinct 
functions. NKT cells from different organs have been reported to have distinct functions. For example, 
double negative (DN) NKT cells in the liver mediate tumor rejection (reference 6), and DN NKT cells 
from the thymus regulate immune cell function in the NOD mouse model of type I diabetes (reference 
8). These functionally distinct populations of NKT cells might arise from the same NKT cell precursors 
in the thymus. However, unidentified organ-specific factors might dictate the function of local NKT 
cell populations. Local dendritic cell populations (either stimulatory or regulatory) that interact with 
NKT cells might also influence local NKT cell function.
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of different NKT cell subsets (10, 11,
20). Consistent with this idea, our own
microarray analyses have shown that
mouse NKT cells from different organs
show substantially different gene ex-
pression patterns, including cytokine-
or chemokine-related and apoptosis-
related genes (unpublished data).
It is also possible that organ-spe-
cific antigen-presenting cells (APCs)
modulate NKT cell function (Fig. 1).
Yang et al. suggested that different
levels of costimulatory molecules ex-
pressed by organ-specific APCs cause
different NKT cell responses (21).
For example, thymic and splenic
APCs induced similar level of IL-4
production by NKT cells, whereas
only splenic APCs induced substan-
tial IFN-
 
 
 
 production. APCs in dif-
ferent organs may also express differ-
ent tissue-specific glycolipid ligands
for NKT cells. A study of the TCRV
 
 
 
repertoires of NKT cells from dif-
ferent organs showed that the DJ
regions among TCRV
 
 
 
8.2
 
 
 
 NKT
cells varied depending on the tissue
of origin (bone marrow, spleen, or
liver), suggesting the possibility that
different endogenous ligands may ex-
ist in the different tissues (22). This
idea is supported by the fact that
several synthetic glycolipids have
been shown to induce different cy-
tokine profiles in NKT cells. OCH,
which is a truncated version of the
prototypic NKT cell ligand 
 
 
 
-Gal-
Cer, induced the production of Th2
cytokines from NKT cells (23). In
contrast, 
 
 
 
-C-GalCer, a C-glycoside
analogue of 
 
 
 
-GalCer, mainly in-
duced the production of Th1 cyto-
kines (24). Thus, APCs in different
tissues may express endogenous OCH-
or 
 
 
 
-C-GalCer–type ligands and
thereby promote differential cytokine
gene expression.
It also seems likely that the unique
anatomical features of the liver could
endow hepatic NKT cells with special-
ized functions. APCs in the liver might
capture and present exogenous glycolip-
ids from the alimentary tract, such as
glycosphingolipids derived from Gram-
negative bacteria including 
 
Ehrlichia
 
 and
 
Sphingomonas
 
 (25, 26) These ligands
might preferentially induce IFN-
 
 
 
-
dependent protective immune responses,
including antitumor responses.
 
Other mechanism determining functions 
of NKT cell subsets
 
NKT cell functions or cytokine pro-
files can be altered by additional
mechanisms, including the modula-
tion of TCR signaling. Kojo et al. re-
cently reported that the frequency of
NKT cell stimulation through the
TCR affects NKT cell function (27).
A single stimulation with 
 
 
 
-GalCer
resulted in the production of high lev-
els of IFN-
 
 
 
 by the NKT cell. This
 
 
 
-GalCer–induced IFN-
 
 
 
 produc-
tion is the basis for the adjuvant effect
of NKT cell activation on NK and
CD8
 
 
 
 T cells, and contributes to
protective immune responses such as
tumor rejection (28). In contrast,
repeated stimulation with 
 
 
 
-GalCer
caused NKT cells to produce more
IL-10 and less (if any) IFN-
 
 
 
, thus fa-
voring the development of regulatory
NKT cells (27). These studies suggest
that the intensity of TCR signals in-
fluences the function of NKT cells,
in a manner similar to the effect of
TCR avidity on positive and negative
selection of developing T cells in the
thymus (29).
Hayakawa et al. described similar
tolerogenic changes in thymic NKT
cells that resulted from chronic stimula-
tion of the TCR (30). They showed
that chronic exposure of mice to 
 
 
 
-Gal-
Cer (weekly for 8 wk) resulted in the
disappearance of existing NKT cells
followed by the thymus-dependent re-
population of the mice with NKT cells
that expressed increased levels of the
inhibitory NK cell receptor Ly-49.
These NKT cells displayed decreased
cytokine production and a reduced
ability to reject tumor cells. Therefore,
the timing and duration of NKT cell
stimulation also seems to be crucial
in determining their functions during
subsequent immune responses. It is not
yet known whether the modulation of
TCR stimulation has an equivalent ef-
fect on distinct subsets of NKT cells. It
will be interesting to examine the pos-
sibility that chronic stimulation has dif-
ferent effects on different subsets of
NKT cells, causing only certain subsets
to become tolerogenic.
 
Concluding remarks
 
In considering any NKT cell–based
immune therapy, it would be advanta-
geous to be able to utilize only those
NKT cells with the desired function.
According to the findings by Crowe et
al. (6) and Terabe et al. (7), it seems
likely that different subsets or types of
NKT cells and their tissue of origin will
be important parameters in targeting
particular NKT cell functions. For
therapeutic purposes, the design of new
glycolipid ligands for NKT cells that
would preferentially activate a func-
tionally specialized NKT cell subset, or
that would activate NKT cells in a par-
ticular organ, would be warranted. Al-
ternative approaches to activate NKT
cells in a particular organ might include
new drug delivery techniques, such as
lipid particles or nanospheres. But be-
fore such therapeutic strategies are pur-
sued, it will be important to determine
the precise correlation between the
phenotype, function, and anatomical
distribution of mouse and especially
human NKT cells.
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